DE69306969D1 - Therapeutisches anti-hiv oligonukleotid und arzneimittel - Google Patents

Therapeutisches anti-hiv oligonukleotid und arzneimittel

Info

Publication number: DE69306969D1
Authority: DE; Germany
Prior art keywords: hiv; oligonucleotides; medicinal product; therapeutic anti; disclosed
Prior art date: 1992-10-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69306969T

Other languages

English (en)

Other versions

DE69306969T2 (de

Inventor

Sudhir Agrawal

Jin Tang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aceragen Inc

Original Assignee

Hybridon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-05

Filing date

1993-10-04

Publication date

1997-02-06

1993-10-04 Application filed by Hybridon Inc filed Critical Hybridon Inc

1997-02-06 Publication of DE69306969D1 publication Critical patent/DE69306969D1/de

1997-05-07 Application granted granted Critical

1997-05-07 Publication of DE69306969T2 publication Critical patent/DE69306969T2/de

2013-10-05 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 4
230000001225 therapeutic effect Effects 0.000 title abstract 2
230000036436 anti-hiv Effects 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
239000002773 nucleotide Substances 0.000 abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 2
208000031886 HIV Infections Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
101710163270 Nuclease Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
230000029087 digestion Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000004713 phosphodiesters Chemical class 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69306969T 1992-10-05 1993-10-04 Therapeutisches anti-hiv oligonukleotid und arzneimittel Expired - Fee Related DE69306969T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US95813592A	1992-10-05	1992-10-05
PCT/US1993/009392 WO1994008004A1 (en)	1992-10-05	1993-10-04	Therapeutic anti-hiv oligonucleotide and pharmaceutical

Publications (2)

Publication Number	Publication Date
DE69306969D1 true DE69306969D1 (de)	1997-02-06
DE69306969T2 DE69306969T2 (de)	1997-05-07

Family

ID=25500631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69306969T Expired - Fee Related DE69306969T2 (de)	1992-10-05	1993-10-04	Therapeutisches anti-hiv oligonukleotid und arzneimittel

Country Status (19)

Country	Link
US (1)	US5684147A (de)
EP (1)	EP0664833B1 (de)
JP (1)	JPH08504570A (de)
KR (1)	KR950704482A (de)
AT (1)	ATE146819T1 (de)
AU (1)	AU678415B2 (de)
BR (1)	BR9307191A (de)
CA (1)	CA2146364A1 (de)
CZ (1)	CZ85495A3 (de)
DE (1)	DE69306969T2 (de)
DK (1)	DK0664833T3 (de)
ES (1)	ES2096343T3 (de)
FI (1)	FI951600A (de)
GR (1)	GR3022315T3 (de)
HU (1)	HUT72400A (de)
NO (1)	NO951307L (de)
NZ (1)	NZ257434A (de)
PL (1)	PL308261A1 (de)
WO (1)	WO1994008004A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US5733781A (en) *	1994-07-19	1998-03-31	Gen-Probe Incorporated	Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6776986B1 (en)	1996-06-06	2004-08-17	Novartis Ag	Inhibition of HIV-1 replication by antisense RNA expression
US6610539B1 (en) *	1997-07-10	2003-08-26	Genesense Technologies, Inc.	Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (de) *	1997-07-10	2005-11-09	GeneSense Technologies Inc.	Antisense oligonukleotid-sequenzen als inhibitoren für mikroorganismen
EP1007657B1 (de)	1997-08-19	2006-02-08	Idera Pharmaceuticals, Inc.	Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
EP1733735B1 (de)	1998-05-22	2017-03-22	Ottawa Hospital Research Institute	Verfahren und Produkte zur Induktion von mukosaler Immunität
JP4854853B2 (ja)	1998-11-12	2012-01-18	ライフテクノロジーズコーポレーション	トランスフェクション薬剤
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6623920B1 (en) *	1999-07-09	2003-09-23	Gen-Probe Incorporated	Detection of HIV-1 by nucleic acid amplification
CA2396677A1 (en) *	1999-12-23	2001-06-28	The Board Of Regents Of The University Of Texas System	Inhibition of cellular proteases
ATE378348T1 (de) *	2000-01-14	2007-11-15	Us Health	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US6582920B2 (en) *	2000-09-01	2003-06-24	Gen-Probe Incorporated	Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) *	2000-10-30	2002-05-08	Tosoh Corp	Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
SG177000A1 (en)	2001-08-17	2012-01-30	Coley Pharm Gmbh	Combination motif immune stimulatory oligonucleotides with improved activity
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8263091B2 (en)	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
ZA200503511B (en)	2002-10-29	2006-10-25	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1627563A1 (de)	2004-08-10	2006-02-22	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
EP1647595A1 (de) *	2004-10-15	2006-04-19	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Nukleinsäuren gegen Viren, insbesondere gegen HIV
US8399423B2 (en) *	2005-10-12	2013-03-19	Idera Pharmaceuticals, Inc.	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
ES2366227T3 (es)	2005-11-17	2011-10-18	TET Systems GmbH & Co. KG	Sistemas de expresión inducibles.
USRE49583E1 (en)	2005-11-17	2023-07-18	Tet Systems Gmbh & Co. Kg	Inducible expression systems
ES2444465T5 (es)	2005-12-09	2023-11-30	Academisch Medisch Centrum Bij De Univ Van Amsterdam	Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
US9005974B2 (en)	2005-12-09	2015-04-14	Academish Medisch Centrum Bij De Universiteit Van Amsterdam	Means and methods for influencing the stability of cells
DK2454283T3 (en)	2009-07-15	2018-05-07	Aimm Therapeutics Bv	METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
CA2793959C (en)	2010-03-25	2019-06-04	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
CN103429615B (zh)	2010-12-02	2018-03-16	埃姆医疗有限公司	用于生产高亲和力抗体的方式和方法
SI2691530T1 (en)	2011-06-10	2018-08-31	Oregon Health & Science University	CMV glycoproteins and recombinant vectors
US20130189754A1 (en)	2011-09-12	2013-07-25	International Aids Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
US9932364B2 (en)	2013-08-26	2018-04-03	The Royal Institution For The Advancement Of Learning/Mcgill University	Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA
EP2848937A1 (de)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en)	2013-10-07	2018-08-28	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
WO2015115892A1 (en)	2014-01-31	2015-08-06	Aimm Therapeutics B.V.	Means and methods for producing stable antibodies
WO2016011203A1 (en)	2014-07-15	2016-01-21	Life Technologies Corporation	Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de)	2015-03-23	2016-09-28	International Aids Vaccine Initiative	Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE68929343T2 (de) *	1988-02-16	2002-09-12	Greatbatch Gen Aid Ltd	Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
AU636573B2 (en) *	1988-02-26	1993-05-06	Worcester Foundation For Biomedical Research, Inc.	Inhibition of htlv-iii by exogenous oligonucleotides

1993
- 1993-10-04 JP JP6509354A patent/JPH08504570A/ja active Pending
- 1993-10-04 HU HU9500995A patent/HUT72400A/hu unknown
- 1993-10-04 CZ CZ95854A patent/CZ85495A3/cs unknown
- 1993-10-04 DE DE69306969T patent/DE69306969T2/de not_active Expired - Fee Related
- 1993-10-04 WO PCT/US1993/009392 patent/WO1994008004A1/en not_active Application Discontinuation
- 1993-10-04 EP EP93924289A patent/EP0664833B1/de not_active Expired - Lifetime
- 1993-10-04 NZ NZ257434A patent/NZ257434A/en unknown
- 1993-10-04 PL PL93308261A patent/PL308261A1/xx unknown
- 1993-10-04 DK DK93924289.7T patent/DK0664833T3/da active
- 1993-10-04 ES ES93924289T patent/ES2096343T3/es not_active Expired - Lifetime
- 1993-10-04 KR KR1019950701317A patent/KR950704482A/ko not_active Application Discontinuation
- 1993-10-04 AT AT93924289T patent/ATE146819T1/de not_active IP Right Cessation
- 1993-10-04 BR BR9307191A patent/BR9307191A/pt not_active Application Discontinuation
- 1993-10-04 AU AU54028/94A patent/AU678415B2/en not_active Ceased
- 1993-10-04 CA CA002146364A patent/CA2146364A1/en not_active Abandoned
1994
- 1994-10-07 US US08/319,823 patent/US5684147A/en not_active Expired - Lifetime
1995
- 1995-04-04 FI FI951600A patent/FI951600A/fi not_active Application Discontinuation
- 1995-04-04 NO NO951307A patent/NO951307L/no unknown
1997
- 1997-01-17 GR GR960403507T patent/GR3022315T3/el unknown

Also Published As

Publication number	Publication date
HU9500995D0 (en)	1995-06-28
NZ257434A (en)	1997-01-29
PL308261A1 (en)	1995-07-24
BR9307191A (pt)	1999-03-30
JPH08504570A (ja)	1996-05-21
EP0664833B1 (de)	1996-12-27
EP0664833A1 (de)	1995-08-02
FI951600A (fi)	1995-05-10
NO951307D0 (no)	1995-04-04
KR950704482A (ko)	1995-11-20
HUT72400A (en)	1996-04-29
CZ85495A3 (en)	1996-03-13
ES2096343T3 (es)	1997-03-01
DE69306969T2 (de)	1997-05-07
US5684147A (en)	1997-11-04
CA2146364A1 (en)	1994-04-14
NO951307L (no)	1995-06-01
DK0664833T3 (da)	1997-04-14
ATE146819T1 (de)	1997-01-15
AU678415B2 (en)	1997-05-29
GR3022315T3 (en)	1997-04-30
WO1994008004A1 (en)	1994-04-14
FI951600A0 (fi)	1995-04-04
AU5402894A (en)	1994-04-26

Legal Events

Date	Code	Title	Description
1998-01-29	8364	No opposition during term of opposition
2000-12-14	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
ATE146819T1 (de)	1997-01-15	Therapeutisches anti-hiv oligonukleotid und arzneimittel
CA2165821A1 (en)	1995-01-05	Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
AU8771398A (en)	1999-03-08	Novel hiv-specific synthetic oligonucleotides and methods of their use
WO1994024144A3 (en)	1995-03-16	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
ATE202383T1 (de)	2001-07-15	Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
ATE181960T1 (de)	1999-07-15	Gegensinnige hemmer des humanen immunmangel virus (hiv)
HU9403788D0 (en)	1995-02-28	Self-stabilized oligonucleotides as therapeutic agents
HUP0103465A2 (hu)	2002-01-28	A VEGF expressziójának gátlására szolgáló rövid oligonukleotidok
PL319512A1 (en)	1997-08-18	Viral material and nucleotidic fragments associated with sclerosis multiplex or diagnostic, prophylactic and therapeutic purposes
KR960704034A (ko)	1996-08-31	단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
AP1674A (en)	2006-10-30	The genome of the HIV-1 inter-subtype (C/B') and use thereof.
NO965017L (no)	1997-01-22	Oligonukleotider med anti-cytomegalovirus aktivitet
EP0733640A4 (de)	1999-11-24	Doppelsträngiges oligonukleotid und karzinostatisches mittel das dieses als aktiven inhaltsstoff enthält
KR960000914A (ko)	1996-01-25	이소프레닐 단백질 트랜스퍼라아제의 발현을 억제하는 올리고뉴클레오티드
MX9703188A (es)	1997-12-31	Acidos nucleicos de aminoacido.
TH23381A (th)	1997-02-10	โอลิโกนิวคลีโอไทด์สำหรับยับยั้งการแสดงลักษณะของไอโซพรีนิลโปรตีนทรานสเฟอเรส
WO2001079487A3 (de)	2002-06-20	Polydesoxyribonukleotide zur hemmung der icam-1-genexpression